Veracyte | VCYT - Selling And Administration Expenses


Veracyte reported $55.71M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Agenus USD 6.21M 4.34M Mar/2026
Agilent USD 475M 10M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
Bruker USD 238.9M 3.2M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Illumina USD 273M 1000K Jun/2026
Intrexon USD 10.31M 41K Jun/2024
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Laboratory Of America USD 611.4M 34.2M Sep/2026
Ligand Pharmaceuticals USD 29.12M 8.29M Jun/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Siemens EUR 3.76B 197M Jun/2026
Sonic Healthcare AUD 2.52B 2.46B Dec/2024
Thermo Fisher Scientific USD 1.86B 46M Sep/2026
Veracyte USD 55.71M 4.87M Jun/2026
Waters USD 405M 11M Jun/2026